Navigation Links
Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity
Date:1/9/2017

BOSTON and SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- Intarcia Therapeutics, Inc. and the California Institute for Biomedical Research (Calibr) today announced a strategic research collaboration focused on the development of a novel peptide therapeutic leveraging Calibr's Stapled-Peptide Platform Technology. Intarcia plans to develop and administer this novel therapy in combination with Exenatide (a GLP-1 receptor agonist and active agent in Intarcia's ITCA 650 product), by leveraging its proprietary Medici Drug Delivery SystemTM.

Under the terms of the agreement, Calibr will receive an upfront grant of Intarcia equity, with additional shares vesting over key development milestones, as well as undisclosed cash payments on achievement of predetermined regulatory and sales milestones.  In addition to the milestone payments, Calibr will be eligible to receive tiered royalties on product sales.

Continue Reading
 (PRNewsFoto/Intarcia Therapeutics, Inc.)
(PRNewsFoto/Intarcia Therapeutics, Inc.)...

Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics, commented: "We are committed to disruptive innovation leveraging our proprietary Medici Drug Delivery SystemTM and we now have several combination products in our pipeline that we believe we can uniquely optimize and deliver in a once- or twice-yearly mini-pump.  We're excited to advance a combination program with Calibr that is targeting significant advances for patients suffering from type 2 diabetes and obesity."

"This collaboration is another example of Calibr's drive to work with innovative partners who are committed to making a difference in human health," said Matt Tremblay, Ph.D., Calibr's Chief Operating Officer. "We look forward to working with Intarcia to leverage our peptide technology platform to create transformative new medicines."

About the Medici Drug Delivery System™
Intarcia's novel technology platform, the Medici Drug Delivery System, is a proprietary subcutaneous delivery system comprised of three unique technologies:

  • A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more
  • A matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication
  • A placement technology including proprietary tools designed to provide an optimal user experience

Once a drug is approved, a trained healthcare professional can place the small device in an in-office procedure. Once in place under the skin, water from the extracellular fluid enters the pump device at one end – by diffusing through a semi-permeable membrane directly into an osmotic engine – that expands to drive a piston at a controlled rate. This allows the drug within the pump to be released in a steady, consistent fashion at the other end of the device. Each osmotic mini-pump is designed to hold an appropriate volume of drug to treat a patient for up to a full year.

About ITCA 650
ITCA 650 is designed as a twice-yearly therapy for the chronic treatment of type 2 diabetes. The investigational therapy employs Intarcia's innovative technology platform, the Medici Drug Delivery System™. In its Phase 3 clinical trials for type 2 diabetes, ITCA 650 was evaluated while delivering a continuous and consistent drug therapy in a three-month initiation dose, followed by consecutive six-month doses. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist that is currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. All four of the global Phase 3 clinical trials for ITCA 650 in type 2 diabetes were successfully completed, and the New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) on November 21, 2016.  If approved, ITCA 650 would be the first and only injection-free GLP-1 receptor agonist therapy. Once-yearly mini-pumps at the 60mcg/day maintenance dose are also in development.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System™. Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes, obesity, autoimmune diseases, HIV, and other serious disorders.

About the California Institute for Biomedical Research, Calibr
The California Institute for Biomedical Research (Calibr) is an independent not-for-profit institute established in 2012 with the goal of accelerating the translation of basic research to new medicines that address unmet medical needs. Collaborations with researchers across the world expedite the translation of basic biomedical findings to new therapies, while enabling commercial partnerships are formed to bring these new medicines to the public. Value created from these activities is reinvested in preclinical and clinical research at the institute to further its mission. In October 2016, Calibr became a corporate affiliate of The Scripps Research Institute. For more information, see www.calibr.org.

Intarcia, Medici and their logos are registered trademarks of Intarcia Therapeutics, Inc.

Follow us on Twitter @intarcia.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intarcia-and-calibr-announce-collaboration-and-in-licensing-deal-aimed-at-delivering-a-next-generation-combination-product-for-diabetes-and-obesity-300387513.html


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
2. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
3. Intarcia Appoints Raymond Keane Vice President, General Counsel, And Chief Legal Officer
4. Intarcia CEO To Present Company Progress, Interim Phase 3 Data, And Key Milestones At J.P. Morgan
5. Intarcia Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q
6. Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes
7. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
8. Intarcia And Numab Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications
9. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation
10. Intarcia Appoints James P. Brady Vice President, Human Resources
11. Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Responding to Heath Ledger,s father,s recent call for ... Chris Cornell in May, the mental health watchdog group, ... psychiatric drug side effects search engine ... risks. The father of the late actor ... has called for tighter rules on prescription drugs. Speaking at ...
(Date:6/7/2017)... DUBLIN , June 7, 2017 Endo ... on June 7, 2017, the Hon. Joseph R. ... District of West Virginia , entered ... Systems, Inc. Pelvic Repair System Products Liability Litigation (the ... filed MDL cases to provide expert disclosures on specific ...
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ... Emergency Management Agency’s (FEMA) recent update of flood zones, more people than ever ... Act was enacted to reflect the actual risk in flood zone areas during ...
(Date:6/23/2017)... ... 2017 , ... Jusino Insurance Services, a locally owned firm ... Chicago metropolitan area, is embarking on a charity drive in conjunction with the ... in 1897, Hephzibah Children’s Association is one of the oldest social services agencies ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been partnering ... in grant funding to support its programs focused on providing opportunity to low-income families ... a grant by the Foundation of $15,000 to support its , Climb to College ...
Breaking Medicine News(10 mins):